How The Covid-19 Vaccines Race Made them Come This Fast


Kathrin Jansen, head of Pfizer’s vaccine research and development, said they assessed all existing technologies, including protein-based vaccines and vaccines using viral vectors.

“They all have too few pros and too many cons,” she said.

Meanwhile, other companies such as Johnson & Johnson and AstraZeneca have chosen to partner with Oxford University. They both focused on viral-vector vaccines while Sanofi and Novavax relied more on proven technology in protein-based vaccines.  

Signup for the USA Herald exclusive Newsletter